{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T02:13:43Z","timestamp":1768097623277,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejogrb.2025.01.025","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T19:55:00Z","timestamp":1736970900000},"page":"160-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Secondary cytoreductive surgery for ovarian cancer recurrence and first-line maintenance therapy: A multicenter retrospective study"],"prefix":"10.1016","volume":"306","author":[{"given":"Stefano","family":"Uccella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Puppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-699X","authenticated-orcid":false,"given":"Simone","family":"Garzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Carlo","family":"Zorzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Leone Roberti Maggiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zavallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Calandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2025.01.025_b0005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0015","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0020","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0025","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0035","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.21037\/gs-20-353","article-title":"Laparotomy vs. minimally invasive surgery for ovarian cancer recurrence: a systematic review","volume":"9","author":"Uccella","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2023.10.021","article-title":"Major vessel resection for complete cytoreduction in primary advanced and recurrent ovarian malignancies: a case series and systematic review of the literature - pushing the boundaries in oncovascular surgery","volume":"179","author":"Uccella","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0045","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jmig.2019.09.789","article-title":"Laparoscopic excision of a 5-cm retroaortic relapse of ovarian cancer","volume":"27","author":"Uccella","year":"2020","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0050","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: what is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0055","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0060","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0070","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2013.04.055","article-title":"Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers","volume":"130","author":"Dao","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0080","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/ijgc-2020-001517","article-title":"Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer","volume":"30","author":"Kim","year":"2020","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0085","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.21037\/atm-20-4448","article-title":"Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature","volume":"8","author":"Turco","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0095","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) (2024) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2024."},{"key":"10.1016\/j.ejogrb.2025.01.025_b0100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0105","first-page":"3484","article-title":"Prognosis following surgery for recurrent ovarian cancer and diagnostic criteria predictive of cytoreduction success: a systematic review and meta-analysis","volume":"13","author":"Gaba","year":"2023","journal-title":"Diagn Basel Switz"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13048-021-00842-9","article-title":"The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"14","author":"Ding","year":"2021","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0115","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","article-title":"Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin","volume":"21","author":"Eveno","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1245\/s10434-017-6235-2","article-title":"Systematic review of cytoreductive surgery and bevacizumab-containing chemotherapy in advanced ovarian cancer: focus on safety","volume":"25","author":"Petrillo","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0125","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0135","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0140","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0150","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0155","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0160","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0170","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0175","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"CD007929","key":"10.1016\/j.ejogrb.2025.01.025_b0180","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","volume":"2","author":"Tattersall","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0190","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/jcmm.14133","article-title":"PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms","volume":"23","author":"Jiang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ejogrb.2025.01.025_b0195","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:43:15Z","timestamp":1740123795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"alternative-id":["S0301211525000259"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.01.025","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreductive surgery for ovarian cancer recurrence and first-line maintenance therapy: A multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}